Annual report pursuant to Section 13 and 15(d)

Segment Information

v3.24.1.u1
Segment Information
 12 Months Ended
Dec. 30, 2023
Segment Reporting [Abstract]  
Segment Information
Note 21: Segment information
The Company operates within targeted markets through three reportable segments for continuing operations: biotechnology, recycling, and technology. The biotechnology segment commenced operations in September 2019 and is focused on development of new and innovative solutions for ending the opioid epidemic ranging from digital technologies to educational advocacy. The recycling segment includes all fees charged and costs incurred for collecting, recycling and installing appliances for utilities and other customers. The recycling segment also includes byproduct revenue, which is primarily generated through the recycling of appliances. The technology segment designed wireless modules to connect devices to the Mobile Internet of Things (“IoT”) which contain location-based service (“LBS”) capabilities and can interface to external sensors to allow them to communicate both sensor status and position information. The nature of products, services and customers for each segment varies significantly. As such, the segments are managed separately. Our Chief Executive Officer has been identified as the Chief Operating Decision Maker (“CODM”). The CODM evaluates performance and allocates resources based on sales and income from operations of each segment. Operating loss represents revenues less cost of revenues and operating expenses, including certain allocated selling, general and administrative costs. There are no intersegment sales or transfers.
The following tables present our segment information (in $000’s):
For the Years Ended
December 30, 2023 December 31, 2022
Revenues
Biotechnology $ —  $ — 
Discontinued operations 3,795  39,611 
Total Revenues $ 3,795  $ 39,611 
Gross profit
Biotechnology $ —  $ — 
Discontinued operations (197) 7,619 
Total Gross profit $ (197) $ 7,619 
Operating income
Biotechnology $ (19,846) $ (3,149)
Discontinued operations 10,438  8,395 
Total Operating income $ (9,408) $ 5,246 
Depreciation and amortization
Biotechnology $ 1,452  $ 2 
Discontinued operations 96  555 
Total Depreciation and amortization $ 1,548  $ 557 
Interest income (expense), net
Biotechnology $ 2,250  $ 468 
Discontinued operations (181) (957)
Total Interest income (expense), net $ 2,069  $ (489)
Net income after provision for income taxes
Biotechnology $ (17,095) $ 8,020 
Discontinued operations 9,283  2,972 
Total Net income after provision for income taxes $ (7,812) $ 10,992 
As of
December 30, 2023		 As of
December 31, 2022
Assets
Biotechnology $ 18,487  $ 29,165 
Discontinue operations —  17,591 
Total Assets $ 18,487  $ 46,756 
Intangible Assets
Biotechnology $ 17,846  $ 19,297 
Discontinued operations —  735 
Total Intangible Assets $ 17,846  $ 20,032